This research was supported by BrightFocus
BrightFocus-funded researcher, Jeremy Herskowitz, Ph.D., has identified a new way to shut down the production of toxic beta-amyloid by relocating a key amyloid-producing protein, called BACE, into another part of the cell where it can do less harm. This indirect way of blocking BACE was accomplished by reducing levels of a brain protein, called ROCK2, which is normally involved with controlling cell movement and shape. The researchers found that they could reduce beta-amyloid when their drug was added to cultured brain cells and when injected directly into the brains of mice designed to show features of Alzheimer’s disease.
There are currently no disease-modifying drugs available for patients with Alzheimer’s disease. A future indirect ROCK2-targeting strategy could not only reduce the production of beta-amyloid, but avoid the toxic side effects that may be seen by other researchers directly targeting BACE and other key proteins. The next step for these researchers will be to deliver this drug by mouth or bloodstream into Alzheimer’s disease mice to confirm whether these biochemical effects translate into the reduction of cognitive issues.
This content was last updated on: Tuesday, June 30, 2015
The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.